Đang chuẩn bị liên kết để tải về tài liệu:
Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Ridaforolimus is a mammalian target of rapamycin inhibitor that has activity in solid tumors. Paclitaxel and carboplatin have broad antineoplastic activity in many cancers. This phase I trial was conducted to determine the safety profile, maximal tolerated dose, and recommended phase II dose and schedule of oral ridaforolimus combined with paclitaxel and carboplatin in patients with solid tumor cancers. | Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers

TÀI LIỆU LIÊN QUAN

Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: Study protocol

A prospective phase I study of hypofractionated neoadjuvant radiotherapy for locally advanced gastric cancer

BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: A first-inhuman phase-I study

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma

Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease smallcell lung cancer (LD-SCLC): TORG 0604

Optimal biological dose: A systematic review in cancer phase I clinical trials

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses

Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: Study protocol

A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.